Drugs / PLD
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT06161025 Comparator | Feb 2024 → Feb 2028 expected | — | Daiichi Sankyo | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06161025 ↗ |
| Route | Intravenous | “PLD will be administered as an IV infusion” NCT06161025 ↗ |